California’s First Hemophilia B Gene Therapy Drug Infusion Conducted at LuskinOIC

Breaking Boundaries: James Deale Becomes California’s First Recipient of Life-Changing Gene Therapy for Hemophilia B

James Deale faced a significant health scare at the age of 22 when he underwent wisdom teeth extraction and was diagnosed with Hemophilia B, a genetic disorder resulting from a deficiency of the blood clotting protein, factor IX. For years, James grappled with regular blood infusions and the constant worry about managing his condition, particularly when traveling. However, thanks to the LuskinOIC Hemophilia Treatment Center, he has become California’s pioneer recipient of a groundbreaking gene therapy drug set to manage his disorder.

“We’re all very excited,” said Doris Quon, MD, Medical Director at the Orthopaedic Hemophilia Treatment Center. “LuskinOIC has played a great role in this therapy because we were part of the phase-three clinical trials, which was the basis for the approval of this drug.”

Since the drug’s approval more than a year ago, six prior infusions have taken place, with the upcoming seventh infusion marking California’s inaugural treatment.

With this revolutionary therapy, James will produce his own factor IX protein, eliminating the need for further infusions. “I feel very positive about this treatment,” he said. “And I think it probably will change my life significantly for years to come.”

Discover the fascinating journey of James Deale, the first Californian to receive a groundbreaking gene therapy for Hemophilia B.

In this inspiring video, learn how James’s life has transformed thanks to the innovative treatment at LuskinOIC Hemophilia Treatment Center. Hear from medical experts and James himself about the impact of this revolutionary therapy on managing his condition. Watch now to see how cutting-edge science is changing lives.